Sushrut S. Waikar, MD, MPH received a BA in English and Neuroscience at Amherst College, his MD at Yale, and an MPH at Harvard. He is the Norman G. Levinsky Professor of Medicine at Chobanian and Avedisian School of Medicine and Chief of Nephrology at Boston Medical Center. Dr. Waikar's research interests and active projects include epidemiologic, translational, and interventional studies to address novel and clinically important questions in nephrology. Current areas of investigation include optimal diagnostic testing in acute kidney injury and chronic kidney disease; biomarkers of kidney pathology and kidney fibrosis; the identification of relevant targets for interventional trials in kidney disease; and randomized controlled trials. He is a Principal Investigator of several NIH grants including the Kidney Precision Medicine Project (U01 DK133092), Multi-omics and Chronic Kidney Disease: Correlation with Histology (R01 DK108803), Discovery Science Collaborative for CKDu (U01 DK130060), NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial (U01AG076789) andThe Boston University Kidney and Medical Engineering Program (BU-KIDMEP, R25 DK128858).
Diversity, Equity, Inclusion and Accessibility
Diversity is a defining and fundamental feature of our biology and society. Diversity allowed for evolution and is a prerequisite for our continued growth as a people. My first memories and experiences with diversity came as a four-year-old immigrant to Chicago, IL by way of a relatively homogenous city in central India. Diversity for me began with an intense feeling of otherness: I had black, white, and brown classmates, but I "belonged" to none of them because of my accented and under-developed English. Growing up in a predominantly white and middle-class neighborhood in suburban Chicago, I struggled to feel comfortable in my own skin, which stood out starkly in class pictures. While my experiences as an immigrant are not unique and were in fact privileged compared to so many, they shaped my appreciation and empathy for others who, like me, don't feel like they quite "belong."
As a resident in internal medicine, I had the great fortune of being assigned to a primary care clinic at San Francisco General Hospital, where virtually none of my patients hailed from the "majority," whether in terms of skin color, income, or freedom from addiction. Later, as a trainee in nephrology, I was exposed to the stark disparities in kidney diseases across so many of these same strata. Now as a member and leader at Boston Medical Center, the institution that proudly serves as the region's safety net hospital, I hope to be able to use my position to advance diversity, equity, inclusion, and accessibility across our institution. My activities in pursuit of social justice and DEIA include the following:
- Commitment to highlighting historical instances of subtle racism in nephrology: for over 20 years, kidney function was estimated differently for black vs. non-black individuals through an equation that initially began as a biostatistical/epidemiological adjustment for "best fit." Over the years, it slowly and belatedly dawned on many in our field that singling out black vs. non-black people while estimating organ function perpetuated a racialized view of humanity. My contributions to this discussion in nephrology include 1) co-authorship on a manuscript on race, genetic ancestry, and kidney function estimation (Hsu et al., New Engl J Med 2021); 2) a perspectives piece entitled "Separate and Unequal: Race-Based Algorithms and Implications for Nephrology" (Schmidt and Waikar, J Am Soc Nephrol. 2021) which highlights other examples of subtle racism in our field; and 3) advocating for and helping to implement the race-neutral kidney function estimating equation at Boston Medical Center.
- Scientific activities on minoritized and marginalized populations: I am a Principal Investigator of the Kidney Precision Medicine Project, a study of the molecular underpinnings of common forms of kidney disease that disproportionately afflict minority populations in the United States. Boston Medical Center has been a major contributor to this effort and in particular on emphasiing the need for recruitment of diverse populations and expanding the scientific focus to social determinants of health. I am also a Principal Investigator of the Chronic Kidney Disease of Uncertain Etiology Consortium, a study of a mysterious kidney disease epidemic afflicting poor agricultural communities in Central America and India. Boston University has been a leader in this scientific investigation for many years, and as of 2021 Boston Medical Center along with co-PI's at Stanford and Beth Israel Deaconess Medical Center are leading the efforts as the Renal Science Core to understand the cause(s) of this condition.
Much work remains to be done in our institution. Areas of focus include:
- Increasing the diversitry of our nephrology faculty to better mirror the diversity of the patients we serve
- Recruiting and training a diverse group of fellows in nephrology at Boston Medical Center and nationally
- Community outreach to neighborhoods to enlist non-academic partners in the pursuit of kidney health
Boston University Chobanian & Avedisian School of Medicine
Pre-Notification transfer from USF for Jie Zhang Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease
04/01/2023 - 03/31/2028 (PI)National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
Multi-Omics and Chronic Kidney Disease: Correlation with Histology
07/15/2022 - 06/30/2027 (PI)New York University Health Resources and
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
08/01/2022 - 07/31/2025 (PI)Brigham and Womens Hospital National Institutes 1U01AG076789-01
Role of Amphiregulin in kidney fibrosis- DK121200
09/15/2019 - 08/31/2024 (PI)Washington University National Institutes 5R01DK121200-03
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
08/20/2020 - 08/20/2024 (PI)Vertex Pharmaceuticals
Boston Chronic Kidney Disease Research Biopsy Center
09/15/2022 - 06/30/2024 (PI)National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS1U01DK133092-01
Discovery Science Collaborative for CKDu
08/25/2021 - 06/30/2024 (PI)Stanford University National Institute o5U01DK130060-03
Biomarker-based Diagnostic Algorithms to Prevent, Detect, and Guide Treatment of Kidney Disease in Persons Living with HIV
09/01/2021 - 05/31/2024 (PI)Northern California Institute for Research and Education National Institute o5R01AG034853-13
Role of Mitochondrial Health in Acute and Chronic Kidney Disease in Older…
09/16/2019 - 04/30/2024 (PI)Northern California Institute for Research and Education National Institutes 5R01AG027002-14
Measuring podocyte urinary biomarkers across renal disorders
04/06/2022 - 04/05/2024 (PI)Pfizer, Inc
Showing 10 of 25 results.
Show All Results
Showing 10 of 52 results.
Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 279 results.
Buckley L, Palsson R, Waikar SS. Linking Kidney Vessel Scarring to Cardiovascular Risk-Reply. JAMA Cardiol. 2023 Oct 01; 8(10):1000. PMID: 37672259
Zhu K, Mukherjee K, Wei C, Hayek SS, Collins A, Gu C, Corapi K, Altintas MM, Wang Y, Waikar SS, Bianco AC, Koch A, Tacke F, Reiser J, Sever S. The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease. Sci Transl Med. 2023 Sep 20; 15(714):eabq6492. PMID: 37729431
Sharma K, Zhang G, Hansen J, Bjornstad P, Lee HJ, Menon R, Hejazi L, Liu JJ, Franzone A, Looker HC, Choi BY, Fernandez R, Venkatachalam MA, Kugathasan L, Sridhar VS, Natarajan L, Zhang J, Sharma VS, Kwan B, Waikar SS, Himmelfarb J, Tuttle KR, Kestenbaum B, Fuhrer T, Feldman H, de Boer IH, Tucci FC, Sedor J, Heerspink HL, Schaub J, Otto EA, Hodgin JB, Kretzler M, Anderton CR, Alexandrov T, Cherney D, Lim SC, Nelson RG, Gelfond J, Iyengar R. Endogenous adenine mediates kidney injury in diabetic models and predicts diabetic kidney disease in patients. J Clin Invest. 2023 Aug 24. PMID: 37616058
Ferkowicz MJ, Verma A, Barwinska D, Ferreira RM, Henderson JM, Kirkpatrick M, Silva PS, Steenkamp DW, Phillips CL, Waikar SS, Sutton TA. Molecular Signatures of Glomerular Neovascularization in a Patient with Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2023 Aug 03.View Related Profiles. PMID: 37533147; DOI: 10.2215/CJN.0000000000000276;
Vasquez-Rios G, Katz R, Levitan EB, Cushman M, Parikh CR, Kimmel PL, Bonventre JV, Waikar SS, Schrauben SJ, Greenberg JH, Sarnak MJ, Ix JH, Shlipak MG, Gutierrez OM. Urinary Biomarkers of Kidney Tubule Health and Mortality in Persons with CKD and Diabetes Mellitus. Kidney360. 2023 Sep 01; 4(9):e1257-e1264. PMID: 37533144; PMCID: PMC10547219; DOI: 10.34067/KID.0000000000000226;
Lake BB, Menon R, Winfree S, Hu Q, Ferreira RM, Kalhor K, Barwinska D, Otto EA, Ferkowicz M, Diep D, Plongthongkum N, Knoten A, Urata S, Mariani LH, Naik AS, Eddy S, Zhang B, Wu Y, Salamon D, Williams JC, Wang X, Balderrama KS, Hoover PJ, Murray E, Marshall JL, Noel T, Vijayan A, Hartman A, Chen F, Waikar SS, Rosas SE, Wilson FP, Palevsky PM, Kiryluk K, Sedor JR, Toto RD, Parikh CR, Kim EH, Satija R, Greka A, Macosko EZ, Kharchenko PV, Gaut JP, Hodgin JB, Eadon MT, Dagher PC, El-Achkar TM, Zhang K, Kretzler M, Jain S. An atlas of healthy and injured cell states and niches in the human kidney. Nature. 2023 Jul; 619(7970):585-594. PMID: 37468583; PMCID: PMC10356613; DOI: 10.1038/s41586-023-05769-3;
Menon R, Otto EA, Barisoni L, Ferreira RM, Limonte CP, Godfrey B, Eichinger F, Nair V, Naik AS, Subramanian L, D'Agati V, Henderson JM, Herlitz L, Kiryluk K, Moledina DG, Moeckel GW, Palevsky PM, Parikh CR, Randhawa P, Rosas SE, Rosenberg AZ, Stillman I, Toto R, Torrealba J, Vazquez MA, Waikar S, Alpers CE, Nelson RG, Eadon MT, Kretzler M, Hodgin JB. Defining the molecular correlate of arteriolar hyalinosis in kidney disease progression by integration of single cell transcriptomic analysis and pathology scoring. medRxiv. 2023 Jun 14.View Related Profiles. PMID: 37398386; PMCID: PMC10312894; DOI: 10.1101/2023.06.14.23291150;
Jiang K, Greenberg JH, Abraham A, Xu Y, Schelling JR, Feldman HI, Schrauben SJ, Waikar SS, Shlipak MG, Wettersten N, Coca SG, Vasan RS, Gutierrez OM, Ix JH, Warady BA, Kimmel PL, Bonventre JV, Parikh CR, Mitsnefes MM, Denburg MR, Furth S. Associations of Biomarkers of Kidney Tubule Health, Injury, and Inflammation with Left Ventricular Hypertrophy in Children with CKD. Kidney360. 2023 Aug 01; 4(8):1039-1047. PMID: 37303083; PMCID: PMC10476681; DOI: 10.34067/KID.0000000000000183;
Sharma K, Zhang G, Hansen J, Bjornstad P, Lee HJ, Menon R, Hejazi L, Liu JJ, Franzone A, Looker HC, Choi BY, Fernandez R, Venkatachalam MA, Kugathasan L, Sridhar VS, Natarajan L, Zhang J, Sharma V, Kwan B, Waikar S, Himmelfarb J, Tuttle K, Kestenbaum B, Fuhrer T, Feldman H, de Boer IH, Tucci FC, Sedor J, Heerspink HL, Schaub J, Otto E, Hodgin JB, Kretzler M, Anderton C, Alexandrov T, Cherney D, Lim SC, Nelson RG, Gelfond J, Iyengar R. Role of endogenous adenine in kidney failure and mortality with diabetes. medRxiv. 2023 Jun 04. PMID: 37398187; PMCID: PMC10312877; DOI: 10.1101/2023.05.31.23290681;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.